Neurocrine Biosciences to Present Advancements at Stifel's 2026 Virtual CNS Forum Explore Neurocrine Biosciences' participation in the Stifel 2026 Virtual CNS Forum, highlighting their commitment to neuroscience and innovative treatments.

Neurocrine Biosciences to Present Advancements at Stifel's 2026 Virtual CNS Forum #USA #San_Diego #Neurocrine_Biosciences #CNS_Forum #NBIX

Citigroup’s 2026 playbook favors tech, healthcare, and financials. Top picks include #ORCL, #NOW, #DOCU in tech; #NBIX, #RCUS, #WAY in healthcare; and #ALLY, #PAYO, #XYZ in financials, driven by earnings strength and improving outlooks.

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy Neurocrine Biosciences (Nasdaq: NBIX) announced that its Phase 3 KINECT-DCP study of valbenazine in pediatric and adult participants with dyskinetic cerebral palsy did not meet primary or key secondary endpoints (Dec. 22, 2025).The 14-week, double-blind, placebo-controlled study—described as the largest trial ever completed in DCP—assessed improvement in chorea. Adverse events were reported as generally consistent with valbenazine's established safety profile. The company thanked patients, families, investigators, and site staff and said it will present full study results at an upcoming scientific meeting.

#NBIX Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical...

#NBIX Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules

www.stocktitan.net/news/NBIX/neurocrine-bio...

#NBIX Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Biosciences Reports Third Quarter 2025 Financial Results SAN DIEGO, Oct. 28, 2025/ PRNewswire/-- Neurocrine Biosciences, Inc. today announced its financial results for the third quarter ended September 30, 2025.. Total net product sales for the third-quarter 2025 were $790 million, reflecting 16% sequential growth over the second quarter of 2025 and 28% growth year-over-year. INGREZZA net product sales for the...

#NBIX Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a≥ 50% improvement in the Abnormal Involuntary Movement Scale Total Score INGREZZA is the only vesicular...

#NBIX Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules

www.stocktitan.net/news/NBIX/neurocrine-bio...

Major Depression Breakthrough: Neurocrine's New Drug Shows Significant Improvement in 8-Week Trial Phase 2 SAVITRI study shows osavampator significantly reduced depression severity vs placebo at Day 28 & 56. Drug well-tolerated with potential as first-in-class AMPA-PAM treatment.

#NBIX Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder

www.stocktitan.net/news/NBIX/neurocrine-bio...

#NBIX #255db164-bef8-45d5-a2cb-7740925904e8 #earningscall-transcripts

Origin | Interest | Match

Neurocrine Biosciences Reports Second Quarter 2025 Financial Results Neurocrine Biosciences (NASDAQ:NBIX) reported strong Q2 2025 financial results with total net product sales of $682 million, representing 17% year-over-year growth. INGREZZA achieved Q2 net product sales of $624 million, while CRENESSITY contributed $53 million with 664 new patient enrollment start forms.The company narrowed its 2025 INGREZZA net product sales guidance to $2.5-$2.55 billion from $2.5-$2.6 billion. Q2 GAAP net income was $107.5 million ($1.06 per share), compared to $65 million ($0.63 per share) in Q2 2024. The company maintains a strong balance sheet with $1.8 billion in cash and marketable securities.Key developments include initiating Phase 3 trials for NBI-'568 in schizophrenia and advancing the pipeline in neuropsychiatry. The company has repurchased $168 million of common stock under its $500 million share repurchase program.

#NBIX Neurocrine Biosciences Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/NBIX/neurocrine-bio...

Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients New AI-powered registry uncovers crucial findings about glucocorticoid dosing needs in CAH patients. Research collaboration brings hope for improved treatment. Learn more.

#NBIX Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 Neurocrine Biosciences (NASDAQ: NBIX) presented one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) at ENDO 2025. The Phase 3 trial, involving 182 adult patients aged 18-58, demonstrated sustained efficacy in treating classic congenital adrenal hyperplasia (CAH).Key findings include 25-30% reduction in glucocorticoid doses while maintaining or improving androstenedione levels. The study showed improvements in insulin resistance and hirsutism in female participants. CRENESSITY demonstrated a favorable safety profile, with headache and fatigue as the most common side effects, mostly mild to moderate and temporary.The data complements previously reported pediatric results and reinforces CRENESSITY's role in CAH management by effectively controlling ACTH and adrenal steroid imbalances while enabling lower, more physiologic steroid dosing.

#NBIX Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Advances Revolutionary Long-Acting Injectable for Rare Disease After Recent FDA Win First-in-human trial begins for innovative long-acting CAH treatment, following Neurocrine's historic FDA approval. Learn how this injectable could transform therapy. See details.

#NBIX Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

www.stocktitan.net/news/NBIX/neurocrine-bio...

First-in-Class Schizophrenia Treatment Achieves Major Clinical Milestone: Phase 2 Success Signals New Era Novel M4 agonist demonstrates significant symptom improvement in schizophrenia patients with favorable safety profile. Phase 3 trial now launching. See full data.

#NBIX Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia Neurocrine Biosciences (NBIX) presented new analyses from a Phase 4 study of INGREZZA® (valbenazine) for tardive dyskinesia at the 2025 ISPOR Conference. The study involved 127 patients who received up to 80mg of INGREZZA for 8 weeks, followed by randomization to continue INGREZZA (n=59) or receive placebo (n=59) for another 8 weeks. Patients receiving INGREZZA showed significant improvements in health-related quality of life measures, including mobility (-0.27), self-care (-0.28), usual activities (-0.36), and pain/discomfort (-0.34). Those continuing INGREZZA for an additional 8 weeks demonstrated further improvements, particularly in mobility (-0.34) and anxiety/depression (-0.38) compared to placebo. The study also revealed significant functional improvements in work/school (-1.37), social life (-1.65), family/home life (-1.30), and SDS total score (-4.28). Continued treatment showed additional benefits in social life (-0.95) and family/home life (-0.89) versus placebo.

#NBIX Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance Neurocrine Biosciences (NBIX) reported strong Q1 2025 financial results, with INGREZZA net product sales reaching $545 million, up 8% year-over-year, and reaffirmed 2025 guidance of $2.5-$2.6 billion. The company's new drug CRENESSITY achieved $14.5 million in first-quarter sales with 413 patient enrollment forms. Key developments include initiating Phase 3 programs for osavampator in major depressive disorder and NBI-'568 in schizophrenia. Q1 2025 total revenues were $572.6 million, with GAAP net income of $7.9 million ($0.08 per share) and non-GAAP net income of $71.5 million ($0.70 per share). The company maintains a strong balance sheet with $1.8 billion in cash and has completed a $300 million share repurchase program while initiating a new $500 million program.

#NBIX Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

www.stocktitan.net/news/NBIX/neurocrine-bio...

New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate Real-world study reveals INGREZZA's superior dosing efficiency: 100% therapeutic success from day one, with better stability vs competitors. Full analysis inside.

#NBIX Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

www.stocktitan.net/news/NBIX/neurocrine-bio...

Breakthrough: INGREZZA Achieves 59% Remission in Tardive Dyskinesia Patients Over 48 Weeks New KINECT 4 data reveals INGREZZA's sustained efficacy across multiple psychiatric conditions, with significant AIMS score improvements in both 40mg and 80mg dose groups.

#NBIX Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

www.stocktitan.net/news/NBIX/neurocrine-bio...

Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions New Phase 3 KINECT-HD data demonstrates INGREZZA's significant impact on chorea symptoms, with remarkable improvements in arms and legs. Key efficacy metrics exceed expectations.

#NBIX Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

www.stocktitan.net/news/NBIX/neurocrine-bio...

Can Neurocrine's New VMAT2 Inhibitor Replicate Its Previous FDA Success? Phase 1 Trial Launches Neurocrine advances its neurology pipeline with second VMAT2 inhibitor entering clinical trials, building on two previous FDA approvals in tardive dyskinesia and Huntington's.

#NBIX Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

www.stocktitan.net/news/NBIX/neurocrine-bio...

Major Win for Neurocrine: Record INGREZZA Sales Hit $615M as New Drug Gets FDA Green Light Neurocrine reports Q4 revenue of $627.7M driven by INGREZZA's strong performance. Company launches CRENESSITY treatment and projects 2025 INGREZZA sales of $2.5-2.6B.

#NBIX Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

www.stocktitan.net/news/NBIX/neurocrine-bio...

Game-Changing Depression Drug Enters Final Testing Phase - Could Help Millions Where Others Failed Neurocrine advances osavampator to Phase 3 trials following successful Phase 2 results, targeting 21M+ Americans with major depression who don't respond to current treatments.

#NBIX Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Expands Global Rights for Depression Drug Osavampator, Phase 3 Trial Ahead Neurocrine secures worldwide rights (ex-Japan) for novel AMPA modulator osavampator in depression treatment. FDA green light sets stage for Phase 3 trials in early 2024.

#NBIX Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Biosciences Taps Former Eli Lilly Executive to Lead Drug Development and Device Innovation Neurocrine Biosciences appoints Andrew Ratz, Ph.D., as SVP of Drug Development, bringing 28 years of experience and 25+ successful product developments from Eli Lilly.

#NBIX Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

www.stocktitan.net/news/NBIX/andrew-ratz-ph...

Neurocrine's CRENESSITY Breakthrough Featured in Major Endocrinology Journal Special Issue Leading endocrinologists highlight CRENESSITY, the first oral CAH treatment, in comprehensive JCEM supplement covering breakthrough advances in congenital adrenal hyperplasia management.

#NBIX Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine's CRENESSITY Breakthrough: First Non-Steroid CAH Treatment Shows Promise in New Study Groundbreaking review highlights CRENESSITY's potential to revolutionize CAH treatment by reducing steroid exposure and improving patient outcomes through novel mechanism of action.

#NBIX Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine Launches CRENESSITY, First-in-Class Treatment for Rare Adrenal Disorder Groundbreaking therapy CRENESSITY now available in US for CAH patients. Features $12 monthly copay for most patients and specialized pharmacy support through PANTHERx Rare.

#NBIX Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

www.stocktitan.net/news/NBIX/neurocrine-bio...

Neurocrine's CRENESSITY Makes History: First New CAH Treatment in 70 Years Gets FDA Approval Groundbreaking therapy shows 4x better results vs placebo in largest-ever CAH trials. Available next week, this milestone treatment will cost most patients under $10 monthly.

#NBIX Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

www.stocktitan.net/news/NBIX/neurocrine-bio...

#NBIX Neurocrine Biosciences to Participate at Investor Conferences in December

www.stocktitan.net/news/NBIX/neurocrine-bio...

News; ( NASDAQ: #NBIX ) Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

#StockMarket #News